Concomitant administration of any proton pump inhibitor (PPI) is not permitted during the study; patients receiving PPI therapy before enrollment must stop using the PPI for days before their first dose of study drugs Chronic concomitant treatment with proton pump inhibitors must discontinue the drug for days prior to registration on the study Patients CANNOT have daily or chronic use of a proton pump inhibitor (PPI) and/or having taken a PPI within days before receiving the first dose of study drug Patients must not be receiving any proton pump inhibitors at the time of registration Participants receiving any medications or substances that are moderate or strong inhibitors or inducers of CYPA within days of registration; proton pump inhibitors (PPI) may be taken while on study, however it is recommended that the PPI is taken hours from the time of palbociclib administration; if needed, alternative antacid therapies may be used including H-receptor antagonists and locally acting antacids; H-receptor antagonists should be administered with a staggered dosing regimen (twice daily); the dosing of palbociclib should occur at least hours after H-receptor antagonist evening dose and hours before the H-receptor antagonist morning dose Subjects requiring daily or chronic use of a proton pump inhibitor (PPI) and/or having taken a PPI within days prior to study registration Daily or chronic use of a proton pump inhibitor (PPI) and/or having taken a PPI within days before receiving the first dose of the study drugs. Patients receiving proton pump inhibitors (PPI) which cannot be discontinued days prior to the start study treatment and for the duration of the study. Patients receiving proton pump inhibitors which cannot be discontinued days prior to the start study treatment and for the duration of the study. Daily or chronic use of a proton pump inhibitor (PPI) and/or having taken a PPI within days before receiving the first dose of study drug. Concomitant administration of any proton pump inhibitor (PPI) is not permitted during the study; patients receiving PPI therapy before enrollment must stop using the PPI for days before their first dose of study drugs Participants who are taking proton pump inhibitors (PPIs) within days of the first dose of study drug or who require treatment with PPIs throughout the trial or those who are taking H receptor antagonists within hours of the first dose of study drug. Daily or chronic use of a proton pump inhibitor (PPI) and/or having taken a PPI within days before receiving the first dose of study drug Patients who are taking proton pump inhibitor (PPI) within days before receiving the first dose of study drug or who require treatment with PPIs throughout the trial or those who are taking H receptor antagonists within hours of the first dose of study drug Patients receiving proton pump inhibitors (PPI) which cannot be discontinued days prior to the start study treatment and for the duration of the study. Daily or chronic use of a proton pump inhibitor (PPI) and/or having taken a PPI within days before receiving the first dose of study drug Daily or chronic use of a proton pump inhibitor (PPI) and/or having taken a PPI within days before receiving the first dose of study drug Daily or chronic use of a proton pump inhibitor (PPI) and/or having taken a PPI within days before receiving the first dose of study drug Subjects currently receiving H-blocker or proton pump inhibitors (or unable to stop at least days prior to the first treatment). Daily or chronic use of a proton pump inhibitor (PPI) and/or having taken a PPI within days before receiving the first dose of study drug Patients who are taking proton pump inhibitor (PPI) within days before receiving the first dose of study drug or who require treatment with PPIs throughout the trial or those who are taking H receptor antagonists within hours of the first dose of study drug Treatment with proton pump inhibitors (PPIs) within days prior to enrollment. Treatment with an H blocker, other than famotidine; if the subject requires a proton pump inhibitor (PPI), then esomeprazole, pantoprazole, or rabeprazole may be given Patient with documented treatment failure of his/her handicap(s) with at least one of the following therapy used at optimized dose: Anti H, Anti H, Proton pump inhibitor, Osteoclast inhibitor, Cromoglycate Sodium, Antileukotriene Subjects must be willing and able to come off any proton pump inhibitor (PPI)/other strong cytochrome P family subfamily A member (CYPA) inhibitors or inducers/simvastatin Treatment with proton pump inhibitors within days prior to study entry Participants requiring daily or chronic use of a proton pump inhibitor (PPI) and/or having taken a PPI within days before receiving the first dose of study drug. Proton pump inhibitors Current or anticipated need for treatment with proton pump inhibitors (PPI); patients on proton pump inhibitors who can be switched to histamine receptor H (H)-blockers before the start of the study are still eligible Patients who are taking proton pump inhibitors within days of the first dose or who require treatment with proton pump inhibitors during the trial or those who are taking H receptor antagonists within hours of the first dose Treatment with proton pump inhibitor (PPI); patients on PPI therapy prior to enrollment must stop using the PPI for at least days prior to the first dose of MLN Has taken proton pump inhibitors within days before the first administration of study drug. Receiving treatment with long acting proton pump inhibitors, and cannot be discontinued days prior to the start of INC treatment and during the course of the study. Concomitant administration of any proton pump inhibitor (PPI) is not permitted during the study; patients receiving PPI therapy before enrollment must stop using the PPI for days before their first dose of study drugs Current therapy with proton pump inhibitors The intermittent use of proton-pump inhibitors (PPI), H-antagonists and antacids (including carafate) is only allowed within these guidelines:\r\n* PPI until day (D)- prior to the first dose of alisertib and prohibited for the duration of the study,\r\n* H antagonists until D- and after the dosing of alisertib is done,\r\n* Antacid formulations until hours before dosing and after hours following dosing Inability to tolerate a proton pump inhibitor (PPI) No concomitant use of proton pump inhibitors (PPI) is allowed; any prior PPI must be discontinued at least one week before receiving MLN (TAK-) Proton RT Regular (>= times per week) use of drugs that alter the pH of the gastrointestinal tract (GI) tract, such as proton pump inhibitors (PPI) and antacids; exceptions: individuals who use prescription PPIs and have approval from their primary health care provider to replace the PPI with an H receptor agonist, i.e. ranitidine, for the duration of the trial will be eligible Participants who regularly (>= times per week) use drugs that alter the pH of the gastrointestinal (GI) tract, such as proton pump inhibitors (PPI) and antacids; exceptions: individuals who use prescription PPIs and have approval from their primary health care provider to discontinue for the duration of clinical trial participation may be enrolled; an alternate drug to control gastroesophageal reflux disease (GERD)/peptic ulcer disease (PUD) symptoms will be suggested Chronic proton pump inhibitor (PPI) use or histamine (H) blocker use that cannot be temporarily discontinued (at least hours) Proton pump inhibitor use at least once daily for at least twelve months prior to enrolment, and stable dose of PPI for the three months before enrolment No use of proton pump inhibitors (PPIs) within the previous months Treatment with long-acting proton pump inhibitors that cannot be discontinued days prior to the start of study drug and during the course of the study Chronic proton pump inhibitor, H-blocker (i.e., ranitidine, famotidine), and/or calcium carbonate use Concurrent use of any proton pump inhibitors